Combinatorial-Designed Nano-Platforms to Overcome Tumor Drug Resistance
The goal of this project is to design libraries of nano-assemblies for encapsulation and targeted delivery of siRNA and small molecule anticancer drugs in order to suppress multidrug resistance.
Development of multidrug resistance (MDR) to conventional and newer generations of anticancer therapeutics is a significant challenge in cancer therapy. MDR is presented clinically as a consequence of many factors that include poor systemic drug delivery efficiency, short residence time, poor permeability into the tumor mass and intracellular availability, as well as micro-environmental selection pressures that give rise to the resistant phenotype.
Drs. Amiji and Duan’s innovative strategy to overcome MDR is based on the development of a novel class of biocompatible dextran-based polymeric nano-assembled structures for encapsulation and delivery of small interference RNA (siRNA) that can silence specific genes in resistant cells, specifically mdr-1 and mrp-1 efflux transporters and Bcl-2 and survivin. These constructs will be also used to deliver cytotoxic therapeutic agents, which could induce maximum cell-kill effect in cancer resistant cells.
Northeastern University’s College of Engineering is home to numerous federally-funded research centers and an array of leading-edge projects and initiatives that advance discovery and new knowledge in health, sustainability, and security.